@article{6a88de635eed4919b27eec915bd09ecf,
title = "A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: An analysis of patients enrolled in GOG 172",
abstract = "Objective: Serum CA-125 values have been advocated in the monitoring of ovarian cancer patients receiving intravenous (IV) chemotherapy. This evaluation sought to determine if the CA-125 test can be used to monitor treatment effect among patients receiving intraperitoneal chemotherapy (IP). Methods: Patient charts from a phase III clinical trial (GOG 172) were retrospectively reviewed. Serum CA-125 levels prior to each cycle of therapy were collected and compared between the IV and IP chemotherapy delivery. The association between CA-125 and progression-free survival (PFS) or overall survival (OS) was estimated and the homogeneity of the results between IP and IV chemotherapy was assessed. Results: A total of 177 patients were treated with IV chemotherapy and 165 patients with IP chemotherapy with CA-125 data available were included in this analysis. The observed difference was not statistically significant in median CA-125 levels between the IV and IP arms at any time point (P > 0.05 for all). Following surgery and adjuvant chemotherapy, patients with an abnormal CA-125 > 35 U/ml were 2.45 times more likely to have disease progression (95% CI: 1.52-3.95, P < 0.001) and 2.78 times more likely to die of disease (95% CI: 1.66-4.65, P < 0.001), compared to those with a CA-125 < 35 U/ml. These results were consistent with IP and IV chemotherapy. Conclusion: Serum CA-125 levels decrease in a similar manner during IP chemotherapy when compared to IV chemotherapy. Serum CA-125 algorithms for monitoring treatment effect that have been established for IV chemotherapy may also be applied for patients receiving IP chemotherapy.",
keywords = "CA-125, Intraperitoneal chemotherapy, Ovarian cancer",
author = "Krivak, {Thomas C.} and Chunqiao Tian and Rose, {G. Scott} and Armstrong, {Deborah K.} and Maxwell, {G. Larry}",
note = "Funding Information: This study was supported by National Cancer Institute grants to the Gynecologic Oncology Group Administrative Office (CA 27469) and the Gynecologic Oncology Group Statistical and Data Center (CA 37517). The following Gynecologic Oncology Group member institutions participated in this study: University of Alabama at Birmingham, Duke University Medical Center, Abington Memorial Hospital, Walter Reed Army Medical Center, University of Minnesota Medical School, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group P.C., University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, Milton S. Hershey Medical Center, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University School of Medicine, Wake Forest University School of Medicine, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St. Luke's Medical Center, University of Kentucky, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University School of Medicine, Columbus Cancer Council, University of Massachusetts Medical School, Women's Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, Tacoma General Hospital, Thomas Jefferson University Hospital, Mayo Clinic, Case Western Reserve University, Tampa Bay Cancer Consortium, North Shore University Hospital, Gynecologic Oncology Network, Ellis Fischel Cancer Center, and Fletcher Allen Health Care. ",
year = "2009",
month = oct,
doi = "10.1016/j.ygyno.2009.06.021",
language = "English (US)",
volume = "115",
pages = "81--85",
journal = "Gynecologic oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",
}